{
    "Clinical Trial ID": "NCT01803282",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Part A: ADX 200 mg",
        "  Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.",
        "INTERVENTION 2: ",
        "  Part A: ADX 600 mg",
        "  Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug."
    ],
    "Eligibility": [
        "Key Inclusion Criteria:",
        "  Part A: histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of standard therapy or for which no standard therapy is available",
        "  Part B: Pancreatic Adenocarcinoma",
        "  Presence of histologically confirmed inoperable locally advanced or metastatic pancreatic adenocarcinoma",
        "  Part B: NSCLC",
        "  Stage IIIB with malignant pleural effusion/pleural seeding or stage IV histologically confirmed NSCLC",
        "  Absence of known epidermal growth factor receptor (EGFR) mutation",
        "  Absence of known translocation or inversion events involving the ALK gene locus (resulting in EML4-ALK fusion)",
        "  Part B: Esophagogastric Adenocarcinoma:",
        "  Histologically confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapsed gastric adenocarcinoma",
        "  Human epidermal growth factor receptor 2 (HER2)-negative tumor (primary tumor or metastatic lesion)",
        "  Part B: First-Line Colorectal Cancer",
        "  Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum",
        "  Radiographically measureable disease",
        "  No prior cytotoxic chemotherapy to treat their metastatic disease",
        "  Part B: Second-Line Colorectal Cancer",
        "  Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum",
        "  Radiographically measureable disease",
        "  Received first-line combination therapy containing oxaliplatin and fluoropyrimidine with or without bevacizumab for metastatic disease with documented evidence of disease progression during or after treatment completion",
        "  Part B: Breast Cancer",
        "  Histologically or cytologically confirmed metastatic breast cancer",
        "  Radiographically measureable disease",
        "  Previous hormonal therapy for metastatic breast cancer or cytotoxic adjuvant chemotherapy is allowed",
        "  Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician",
        "  HER-2 negative tumor (primary tumor or metastatic lesion)",
        "  Adequate organ function",
        "  Key Exclusion Criteria:",
        "  Pregnant or lactating",
        "  Individuals with known central nervous system (CNS) metastases, unless metastases are treated and stable and the individual does not require systemic steroids",
        "  Myocardial infarction, symptomatic congestive heart failure, unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months",
        "  Anti-tumor therapy within 28 days of study drug dosing; concurrent use of hormone therapy for breast or prostate cancer is permitted",
        "  Note: Other protocol defined Inclusion/Exclusion criteria may apply."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants Experiencing Treatment-Emergent Adverse Events",
        "  [Not Specified]",
        "Time frame: Part A: First dose date up to 32 weeks plus 30 days; Part B: First dose date up to 181 weeks plus 30 days",
        "Results 1: ",
        "  Arm/Group Title: Part A: ADX 200 mg",
        "  Arm/Group Description: Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.",
        "  Overall Number of Participants Analyzed: 4",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  100.0",
        "Results 2: ",
        "  Arm/Group Title: Part A: ADX 600 mg",
        "  Arm/Group Description: Participants with advanced solid tumors who had failed or were intolerant to standard therapy or for whom no standard therapy existed, received 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.",
        "  Overall Number of Participants Analyzed: 3",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  100.0"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/4 (0.00%)",
        "  Anaemia 0/4 (0.00%)",
        "  Febrile neutropenia 0/4 (0.00%)",
        "  Leukocytosis 0/4 (0.00%)",
        "  Neutropenia 0/4 (0.00%)",
        "  Pancytopenia 0/4 (0.00%)",
        "  Acute coronary syndrome 0/4 (0.00%)",
        "  Acute myocardial infarction 0/4 (0.00%)",
        "  Atrial fibrillation 0/4 (0.00%)",
        "  Atrial flutter 0/4 (0.00%)",
        "  Cardiac arrest 0/4 (0.00%)",
        "  Pericardial effusion 0/4 (0.00%)",
        "Adverse Events 2:",
        "  Total: 0/3 (0.00%)",
        "  Anaemia 0/3 (0.00%)",
        "  Febrile neutropenia 0/3 (0.00%)",
        "  Leukocytosis 0/3 (0.00%)",
        "  Neutropenia 0/3 (0.00%)",
        "  Pancytopenia 0/3 (0.00%)",
        "  Acute coronary syndrome 0/3 (0.00%)",
        "  Acute myocardial infarction 0/3 (0.00%)",
        "  Atrial fibrillation 0/3 (0.00%)",
        "  Atrial flutter 0/3 (0.00%)",
        "  Cardiac arrest 0/3 (0.00%)",
        "  Pericardial effusion 0/3 (0.00%)"
    ]
}